This is a working overview of research compound, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-21 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
=== First isolation of DNA === Working in the 19th century, biochemists initially isolated DNA and RNA (mixed together) from cell nuclei. They were relatively quick to appreciate the polymeric nature of their "nucleic acid" isolates, but realized only later that nucleotides were of two types—one containing ribose and the other deoxyribose. It was this subsequent discovery that led to the identification and naming of DNA as a substance distinct from RNA. Friedrich Miescher (1844–1895) discovered a substance he called "nuclein" in 1869. Somewhat later, he isolated a pure sample of the material now known as DNA from the sperm of salmon, and in 1889 his pupil, Richard Altmann, named it "nucleic acid". This substance was found to exist only in the chromosomes. In 1919 Phoebus Levene at the Rockefeller Institute identified the components (the four bases, the sugar and the phosphate chain) and he showed that the components of DNA were linked in the order phosphate-sugar-base. He called each of these units a nucleotide and suggested the DNA molecule consisted of a string of nucleotide units linked together through the phosphate groups, which are the 'backbone' of the molecule. However Levene thought the chain was short and that the bases repeated in the same fixed order. Torbjörn Caspersson and Einar Hammersten showed that DNA was a polymer.
== Extraction == Extraction using superheated water tends to be fast because diffusion rates increase with temperature. Organic materials tend to increase in solubility with temperature, but not all at the same rate. For example, in extraction of essential oils from rosemary and coriander, the more valuable oxygenated terpenes were extracted much faster than the hydrocarbons. Therefore, extraction with superheated water can be both selective and rapid, and has been used to fractionate diesel and woodsmoke particulates. Superheated water is being used commercially to extract starch material from marsh mallow root for skincare applications and to remove low levels of metals from a high-temperature resistant polymer. For analytical purposes, superheated water can replace organic solvents in many applications, for example extraction of PAHs from soils and can also be used on a large scale to remediate contaminated soils, by either extraction alone or extraction linked to supercritical or wet oxidation.
Potentiometric and/or spectrophotometric data: PSEQUAD Potentiometric data: HYPERQUAD, BEST, ReactLab pH PRO Spectrophotometric data: HypSpec, SQUAD, SPECFIT, ReactLab EQUILIBRIA., suprafit NMR data HypNMR, WINEQNMR2 Archived 2019-07-14 at the Wayback Machine, suprafit In biochemistry, formation constants of adducts may be obtained from Isothermal titration calorimetry (ITC) measurements. This technique yields both the stability constant and the standard enthalpy change for the equilibrium. It is mostly limited, by availability of software, to complexes of 1:1 stoichiometry.
Sources: en.wikipedia.org
=== Alcohol dependence === Nalmefene is used in the European Union to reduce alcohol dependence and NICE recommends the use of nalmefene to reduce alcohol consumption in combination with psychological support for people who drink heavily. Based on a meta analysis, the usefulness of nalmefene for alcohol dependence is unclear. Nalmefene, in combination with psychosocial management, may decrease the amount of alcohol drunk by people who are alcohol dependent. The medication may also be taken "as needed", when a person feels the urge to consume alcohol.
=== Metabolomics === Borchers has also applied MRM-based mass spectrometry to targeted metabolomics. With Jun Han, he developed an LC–MS/MS method for profiling bile acids in human and mouse blood, combining the assay with a phospholipid-depletion solid-phase extraction step, which allowed a number of minor bile acids to be quantified in blood for the first time. The same collaboration produced a method for quantifying short-chain fatty acids in human feces, in which the acids are chemically derivatized with 3-nitrophenylhydrazine and measured against isotope-labelled internal standards.
Epulis fissuratum is a benign hyperplasia of fibrous connective tissue which develops as a reactive lesion to chronic mechanical irritation produced by the flange of a poorly fitting denture. More simply, epulis fissuratum is where excess folds of firm tissue form inside the mouth, as a result of rubbing on the edge of dentures that do not fit well. It is a harmless condition and does not represent oral cancer. Treatment is by simple surgical removal of the lesion, and also by adjustment of the denture or provision of a new denture. It is a closely related condition to inflammatory papillary hyperplasia, but the appearance and location differs.
===== Pore size ===== In a microporous material where physisorption and weak van der Waals forces dominate adsorption, the storage density is greatly dependent on the size of the pores. Calculations of idealized homogeneous materials, such as graphitic carbons and carbon nanotubes, predict that a microporous material with 7 Å-wide pores will exhibit maximum hydrogen uptake at room temperature. At this width, exactly two layers of hydrogen molecules adsorb on opposing surfaces with no space left in between. 10 Å-wide pores are also of ideal size because at this width, exactly three layers of hydrogen can exist with no space in between. (A hydrogen molecule has a bond length of 0.74 Å with a van der Waals radius of 1.17 Å for each atom; therefore, its effective van der Waals length is 3.08 Å.)
Sources: en.wikipedia.org
Iraqi commandos infiltrated the Kuwaiti border first to prepare for the major units, which began the attack at midnight. The Iraqi attack had two prongs, with the primary attack force driving south straight for Kuwait City down the main highway, and a supporting attack force entering Kuwait farther west, but then turning and driving east, cutting off Kuwait City from the country's southern half. The commander of a Kuwaiti armored battalion, 35th Armoured Brigade, deployed them against the Iraqi attack and conducted a robust defense at the Battle of the Bridges near Al Jahra, west of Kuwait City. Kuwaiti aircraft scrambled to meet the invading force, but approximately 20% were lost or captured. A few combat sorties were flown against Iraqi ground forces. The main Iraqi thrust into Kuwait City was conducted by commandos deployed by helicopters and boats to attack the city from the sea, while other divisions seized the airports and two airbases. The Iraqis attacked the Dasman Palace, the Royal Residence of Kuwait's emir, Jaber Al-Ahmad Al-Jaber Al-Sabah, which was defended by the Emiri Guard supported with M-84 tanks. In the process, the Iraqis killed Fahad Al-Ahmed Al-Jaber Al-Sabah, the Emir's youngest brother. Within 12 hours, most resistance had ended within Kuwait, and the royal family had fled, allowing Iraq to control most of Kuwait. After two days of intense combat, most of the Kuwaiti military were either overrun by the Iraqi Republican Guard, or had escaped to Saudi Arabia. The emir and key ministers fled south along the highway for refuge in Saudi Arabia.
=== Mortality === Mortality is increased in people with AS and circulatory disease is the most frequent cause of death. People with AS have an increased risk of 60% for cerebrovascular mortality, and an overall increased risk of 50% for vascular mortality. About one third of those with ankylosing spondylitis have severe disease, which reduces life expectancy. As increased mortality in ankylosing spondylitis is related to disease severity, factors negatively affecting outcomes include:
== Re-activity (1980–2000) == In 1980, old friend (and fellow ex-Sinner) Dave Machan persuaded Ron to perform again, along with vocalist Kathy Monaco this time in a folk based group called Trinity (Ron played bass for this group). Trinity recorded an albums' worth of material at Dayson Studios (owned by George Day and also home to much of the work done by Ron Wray for the History of Syracuse Music releases) which still remains unreleased. Though Trinity was successful on the nightclub scene, Ron wanted to return to the rock music that was his first love, and tried to re-form The Saint and the Sinners which soon changed their name to East Side Story (later East Side). East Side specialized in classic oldies and seventies hard rock. This band lasted (with virtually the same line-up) for fifteen years before folding in 2000. Some of the members of East Side were Graham Daniels (1984–2000), Larry Brennan (1984–2000), Tom DiRenzo (1988–2000), John Mirra (1991–1993; 1997–2000), Earl "the Pearl" Hamilton (formerly of The New York Flyers now with Redline (1994–1997), Dave Machan (1984–1987) and Barry Glisker (1984–1989).
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.